Gabriel Martinez
Medical · McAllen, TXNPI 1386079770
Payments from drug & device makers
Across 213 payments — averaging $18.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$565
- Lilly USA, LLC$560
- AbbVie$432
- Amarin Pharma, Inc.$423
- AstraZeneca$386
- GSK$315
- plus $1K from 18 others
What the payments were for
- Food & beverage$3,84995%
- Education$1945%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 30 | $565 |
| Lilly USA, LLC | 29 | $560 |
| AbbVie | 32 | $432 |
| Amarin Pharma, Inc. | 25 | $423 |
| AstraZeneca | 18 | $386 |
| GSK | 16 | $315 |
| Astellas Pharma US Inc | 5 | $246 |
| Abbott | 10 | $218 |
| Ironwood Pharmaceuticals, Inc | 10 | $162 |
| Boehringer Ingelheim | 7 | $148 |
| Amgen | 5 | $89 |
| Dexcom, Inc. | 2 | $81 |
| Johnson & Johnson | 4 | $74 |
| Optinose US, Inc. | 3 | $50 |
| Organon | 2 | $46 |
| Sanofi Pasteur Inc. | 3 | $40 |
| Pfizer | 2 | $34 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| Esperion Therapeutics, Inc. | 2 | $32 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Axsome Therapeutics, Inc. | 1 | $27 |
| Intuity Medical Inc | 1 | $25 |
| Phadia US Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,043 in reported general payments places this provider in the 80th percentile of 1,490 medical providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 25 | $31,137 |
| FarxigaDapagliflozin Propanediol | 23 | $29,044 |
| JardianceEmpagliflozin | 17 | $17,732 |
| VascepaIcosapent Ethyl | 15 | $7,840 |
| Rosuvastatin Calcium | 91 | $1,251 |
| Atorvastatin Calcium | 64 | $470 |
| Olmesartan Medoxomil | 35 | $467 |
| Levothyroxine Sodium | 68 | $433 |
| Losartan Potassium | 44 | $360 |
| Pioglitazone Hcl | 27 | $352 |
| Ezetimibe | 22 | $314 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 26 | $278 |
| Tamsulosin Hcl | 19 | $248 |
| Omeprazole | 21 | $232 |
| Vitamin D2Ergocalciferol (Vitamin D2) | 28 | $215 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $565 | $31,13725 claims |
| AstraZenecaFarxiga | $386 | $29,04423 claims |
| Boehringer IngelheimJardiance | $148 | $17,73217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,490 medical providers in Texas.
Other medical in McAllen
- Jason HenslerMcAllen$66K
- Edgar GarciaMcAllen$17K
- Claudia MaldonadoMcAllen$15K
- Rolando VelazquezMcAllen$13K
- Jose de la CerdaSan Antonio$1.1M
- Mark DavisFort Worth$1M
- Joey Dixon-JulianBoerne$458K
- Terry FaleyeKingwood$243K
- Kimberly PoarchDallas$166K
- Erin DuhaimeDallas$150K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.